Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | GRM5 | P41594 | 15/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | OGA | O60502 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30717371 | 0.89 | PDK2 (0.35) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717354 | 0.89 | NPC1 (0.36) | CNR2GRM5NPC1RAB9AOGA | |
| SCHEMBL30717524 | 0.89 | OGA (0.37) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717557 | 0.89 | GRM5 (0.35) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717513 | 0.88 | GRM5 (0.35) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717419 | 0.86 | NPC1 (0.39) | CNR2GRM5NPC1RAB9AOGA | |
| SCHEMBL30717457 | 0.85 | OGA (0.33) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717334 | 0.85 | OGA (0.35) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717413 | 0.84 | OGA (0.37) | GRM5NPC1RAB9AOGA | |
| SCHEMBL30717347 | 0.83 | GRM5 (0.47) | GRM5NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | claimed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | claimed |
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | MIRONID LIMITED (GB) | 2025-12-25 | — | — | US | disclosed |
| EP-4572762-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | Mironid Limited (GB) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038128-A1 | COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS | MIRONID LIMITED (GB) | 2024-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388604-A1 | Compounds and Their Use as PDE4 Activators | PDE4A, PDE7A, PDE4B | HDAC6 1033/4885CNR2 799/4885GRM5 2029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.